Johnson & Johnson (NYSE:JNJ) Shares Sold by WBH Advisory Inc.

WBH Advisory Inc. lessened its stake in Johnson & Johnson (NYSE:JNJGet Rating) by 2.3% in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 43,123 shares of the company’s stock after selling 1,025 shares during the quarter. Johnson & Johnson accounts for about 1.0% of WBH Advisory Inc.’s portfolio, making the stock its 29th largest holding. WBH Advisory Inc.’s holdings in Johnson & Johnson were worth $7,691,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in Johnson & Johnson by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 238,141,110 shares of the company’s stock worth $42,205,749,000 after purchasing an additional 3,358,478 shares during the period. BlackRock Inc. raised its holdings in Johnson & Johnson by 0.4% in the 1st quarter. BlackRock Inc. now owns 200,799,189 shares of the company’s stock worth $35,587,638,000 after purchasing an additional 777,837 shares during the period. State Street Corp raised its holdings in Johnson & Johnson by 1.8% in the 4th quarter. State Street Corp now owns 144,677,639 shares of the company’s stock worth $24,750,004,000 after purchasing an additional 2,492,359 shares during the period. Wellington Management Group LLP raised its holdings in Johnson & Johnson by 0.8% in the 1st quarter. Wellington Management Group LLP now owns 32,772,594 shares of the company’s stock worth $5,808,286,000 after purchasing an additional 265,330 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in Johnson & Johnson by 1.6% in the 1st quarter. Bank of New York Mellon Corp now owns 32,070,396 shares of the company’s stock worth $5,683,837,000 after purchasing an additional 509,818 shares during the period. Institutional investors and hedge funds own 68.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the company. Citigroup reduced their target price on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. UBS Group reduced their target price on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Morgan Stanley reduced their target price on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a report on Monday, September 12th. SVB Leerink reduced their target price on Johnson & Johnson from $200.00 to $194.00 in a report on Wednesday, July 20th. Finally, Wells Fargo & Company increased their target price on Johnson & Johnson from $190.00 to $195.00 and gave the company an “overweight” rating in a report on Wednesday, July 13th. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $189.78.

Johnson & Johnson Price Performance

JNJ stock opened at $166.18 on Friday. The firm has a market capitalization of $436.92 billion, a PE ratio of 24.19, a price-to-earnings-growth ratio of 2.95 and a beta of 0.61. Johnson & Johnson has a 1 year low of $155.72 and a 1 year high of $186.69. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.17. The business has a 50 day simple moving average of $168.06 and a 200-day simple moving average of $174.12.

Johnson & Johnson (NYSE:JNJGet Rating) last issued its quarterly earnings data on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping the consensus estimate of $2.57 by $0.02. The company had revenue of $24.02 billion during the quarter, compared to analyst estimates of $23.85 billion. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. During the same period in the prior year, the business posted $2.48 earnings per share. Equities research analysts anticipate that Johnson & Johnson will post 10.7 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were given a $1.13 dividend. The ex-dividend date was Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.72%. Johnson & Johnson’s payout ratio is 65.79%.

Johnson & Johnson declared that its Board of Directors has authorized a stock repurchase program on Wednesday, September 14th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the company to repurchase up to 1.2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company’s board believes its stock is undervalued.

About Johnson & Johnson

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.